Sangui BioTech:

• Increase in sales of 250% in the first half of the year
• Operating gain in the first half of the year

Hamburg, February 12, 2025:
In the first six months of fiscal year 2025 (to 30/06/2025) Sangui BioTech International Inc. achieved revenues from royalty income of USD 191,326. In the same period of the previous year the comparable revenue amounted to USD 54,876. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first six-month period of the year increased by 250% compared to the same period of the previous year.

Operating expenses increased USD 13,549 or 21% to USD 77,134 during the first half year. As a result of the above factors, the six-month operating result increased USD 122,901 from an operating loss of USD 8,709 to an operating gain of USD 114,192.

Due to the higher exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting exchange rate gain from the valuation of loans denominated in EURO, a positive half year result of USD 120,528 had occurred. Compared to the previous year, in which a loss of USD 31,659 had to be recorded in the comparable period, the half year result improved by USD 152,187.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---